Analyst Price Targets — SKYE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 6, 2025 4:12 pm | — | Craig-Hallum | $2.00 | $1.88 | TheFly | Skye Bioscience downgraded to Hold from Buy at Craig-Hallum |
| October 6, 2025 2:19 pm | — | Cantor Fitzgerald | $2.00 | $2.12 | TheFly | Skye Bioscience downgraded to Neutral from Overweight at Cantor Fitzgerald |
| September 10, 2024 4:30 am | Jonathan Wolleben | JMP Securities | $15.00 | $6.35 | TheFly | Skye Bioscience initiated with an Outperform at JMP Securities |
| August 26, 2024 8:15 am | Albert Lowe | Craig-Hallum | $18.00 | $5.97 | StreetInsider | Craig-Hallum Reiterates Buy Rating on Skye Bioscience (SKYE) |
| June 10, 2024 5:17 pm | Jay Olson | Oppenheimer | $21.00 | $9.98 | StreetInsider | Skye Bioscience (SKYE) PT Lowered to $21 at Oppenheimer |
| May 23, 2024 6:05 am | Kristen Kluska | Cantor Fitzgerald | $21.00 | $11.98 | TheFly | Skye Bioscience initiated with an Overweight at Cantor Fitzgerald |
| April 11, 2024 4:14 pm | Jay Olson | Oppenheimer | $25.00 | $12.69 | StreetInsider | Oppenheimer Starts Skye Bioscience (SYKE) at Outperform Following Uplisting to Nasdaq (correction) |
| March 14, 2024 10:41 am | Edward Tenthoff | Piper Sandler | $20.00 | $12.90 | StreetInsider | Skye Bioscience (SKYE) PT Raised to $20 at Piper Sandler |
Latest News for SKYE
Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biopharmaceutical company pioneering next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025, along with key accomplishments and…
SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Tuesday, March 10th at 1:30 p.m. PT/4:30 p.m.
Shares of Skye Bioscience, Inc. (NASDAQ: SKYE - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, four have assigned a buy recommendation
Skye Bioscience, Inc. (NASDAQ: SKYE) on Monday shared interim 52-week data from the combination therapy arms in the extension phase of the Phase 2a CBeyond proof-of-concept study of nimacimab.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SKYE.
U.S. House Trading
No House trades found for SKYE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.